Program
nelistotug
Also written as “Nelistotug” and “GSK6097608”.
Its studies are mostly in Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck, led by GlaxoSmithKline.
Furthest: phase 2, since Nov 9, 20186 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 64 open or running | phase 2since Nov 9, 2018 | Nov 9, 2018 | Dec 31, 2026phase 1 · NCT04446351 |
Also a collaborator on its studies: iteos-therapeutics, 23andme-inc and iteos-belgium-sa.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2018First study: phase 2 study in NeoplasmsFirst studyNCT03739710 · 175 enrolled · United States, Canada, France and more
- Jun 22, 2020Phase 1 study in NeoplasmsNCT04446351 · 107 enrolled · United States, Canada, Japan and more
- Mar 3, 2022Phase 1 study in NeoplasmsNCT05277051 · 152 enrolled · United States, Australia, Canada and more
- Sep 30, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05565378 · 351 enrolled · United States, Argentina, Belgium and more
- Sep 21, 2023Phase 2 study in Head and Neck NeoplasmsNCT06062420 · 316 enrolled · United States, Argentina, Brazil and more
- Apr 11, 2025Phase 2 study in NeoplasmsNCT06926673 · 62 enrolled · United States, Canada, France and more
Ahead
- Dec 31, 2026Primary completion: phase 1 study in NeoplasmsNCT04446351
TargetBeta
CD96 →read by rule
“A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor CD96 (Tactile; T cell activation increased late expression), ”NCIt, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06926673Neoplasms · United States, Canada, France and more | 2 | Completed | May 2, 2024 | 62 |
| NCT06062420Head and Neck Neoplasms · United States, Argentina, Brazil and more | 2 | Active, not recruiting | Sep 10, 2026 | 316 |
| NCT05565378Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 2 | Active, not recruiting | Oct 26, 2026 | 351 |
| NCT05277051Neoplasms · United States, Australia, Canada and more | 1 | Active, not recruiting | Jun 30, 2026 | 152 |
| NCT04446351Neoplasms · United States, Canada, Japan and more | 1 | Active, not recruiting | Dec 31, 2026 | 107 |
| NCT03739710Neoplasms · United States, Canada, France and more | 2 | Completed | May 2, 2024 | 175 |
How it is read
Names in the registry
- “Nelistotug”, 4 entries
- “GSK6097608”, 2 entries
Conditions, from the studies’ own filings
- Neoplasms, 3 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.